EDN1 and osteosarcoma: Regarding the potential impact of macitentan treatment on osteosarcoma’s resistance to conventional chemotherapy, several studies have demonstrated that ET1 was associated with chemoresistance to doxorubicin and cisplatin [27,41,42,43], suggesting that macitentan treatment may reduce such resistance.